Secondary Logo

Journal Logo

Continuing Medical Education Questions: May 2013

DeVault, Kenneth R MD, FACG; Kumaravel, Arthi MD; Macaron, Carole MD; Albeldawi, Mazen MD; Mehta, Paresh MD

American Journal of Gastroenterology: May 2013 - Volume 108 - Issue 5 - p 693
doi: 10.1038/ajg.2013.117
Practice Guidelines
Free

If you wish to receive credit for this activity, please refer to the Web site:http://acgjournalcme.gi.org/.

Article Title: ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE)

Back to Top | Article Outline

QUESTIONS:

  1. Which one of the following statements regarding esophageal eosinophilia is correct?
    • A. Isolated esophageal eosinophilia is commonly found in gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), and proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE).
    • B. Esophageal eosinophilia does not occur in systemic disorders.
    • C. Esophageal eosinophilia occurs only in EoE.
    • D. The different conditions causing isolated esophageal eosinophilia can be distinguished based on the eosinophil count and other morphological features.
  2. Which one of the following statements regarding the diagnosis of EoE is correct?
    • A. EoE is seen more commonly in females.
    • B. The finding of fixed rings, longitudinal furrows, white exudates or plaques, and esophageal lacerations induced by the passage of the endoscope are pathognomonic and diagnostic of EoE.
    • C. The finding of ≥15 eosinophils in at least one microscopy high-power field on esophageal biopsy after a proton pump inhibitor (PPI) trial is consistent with the diagnosis of EoE in the appropriate clinical setting.
    • D. In addition to esophageal biopsies, biopsies of the gastric antrum and duodenum should be obtained in all patients.
  3. Which one of the following statements regarding the management of EoE is correct?
    • A. Prednisone is the first-line pharmacologic therapy for the treatment of EoE.
    • B. Esophageal dilation in EoE patients carries the same perforation rate as dilation for other benign diseases.
    • C. Mast cell stabilizers, leukotriene inhibitors, and biologic therapies can be used to treat EoE.
    • D. Maintenance therapy is not required for patients with EoE.
© The American College of Gastroenterology 2013. All Rights Reserved.